Literature DB >> 24168187

Regulation of EMT by Notch signaling pathway in tumor progression.

Yumei Li, Jia Ma, Xiujuan Qian, Qiong Wu, Jun Xia, Lucio Miele, Fazlul H Sarkar, Zhiwei Wang1.   

Abstract

Notch signaling pathway has been reported to play critical roles in the development and progression of human cancers because Notch signaling pathway is critically involved in many cellular processes including cell proliferation, survival, apoptosis, migration, invasion, angiogenesis, and metastasis. Emerging evidence suggests that Notch regulates EMT (Epithelial-to-Mesenchymal Transition), leading to tumor invasion and metastasis. Thus, this mini-review is focused on discussing the novel role of Notch signaling pathway in the regulation of EMT. Moreover, we summarized that Notch signaling pathway could be down-regulated by its inhibitors or natural compounds, resulting in the reversal of EMT to MET (Mesenchymal-to-Epithelial Transition), which could be a promising strategy for achieving better treatment outcome in patients diagnosed with cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24168187     DOI: 10.2174/15680096113136660101

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  42 in total

1.  Epithelial-mesenchymal transition: a new target in anticancer drug discovery.

Authors:  Fabrizio Marcucci; Giorgio Stassi; Ruggero De Maria
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

2.  Sulfatase 1: a new Jekyll and Hyde in hepatocellular carcinoma?

Authors:  Rosa M Pascale; Diego F Calvisi; Francesco Feo
Journal:  Transl Gastroenterol Hepatol       Date:  2016-05-18

3.  Notch signaling modulates proliferative vitreoretinopathy via regulating retinal pigment epithelial-to-mesenchymal transition.

Authors:  Jingjing Zhang; Gongqiang Yuan; Muchen Dong; Ting Zhang; Gao Hua; Qingjun Zhou; Weiyun Shi
Journal:  Histochem Cell Biol       Date:  2016-09-07       Impact factor: 4.304

4.  Bone morphogenetic protein 2 mediates epithelial-mesenchymal transition via AKT and ERK signaling pathways in gastric cancer.

Authors:  Anyan Liao; Weijie Wang; Dawei Sun; Yuliang Jiang; Suqing Tian; Jinna Li; Xiangshan Yang; Ranran Shi
Journal:  Tumour Biol       Date:  2014-12-03

5.  SDF-1/CXCR4 Axis Regulates Cell Cycle Progression and Epithelial-Mesenchymal Transition via Up-regulation of Survivin in Glioblastoma.

Authors:  Anyan Liao; Ranran Shi; Yuliang Jiang; Suqing Tian; Panpan Li; Fuxi Song; Yalan Qu; Jinna Li; Haiqin Yun; Xiangshan Yang
Journal:  Mol Neurobiol       Date:  2014-11-25       Impact factor: 5.590

6.  CXCR7 signaling induced epithelial-mesenchymal transition by AKT and ERK pathways in epithelial ovarian carcinomas.

Authors:  Hao Yu; Linlin Zhang; Peishu Liu
Journal:  Tumour Biol       Date:  2014-10-31

7.  Prognostic implication of NOTCH1 in early stage oral squamous cell cancer with occult metastases.

Authors:  Shan Wang; Haixia Fan; Jiankai Xu; Eryang Zhao
Journal:  Clin Oral Investig       Date:  2017-09-02       Impact factor: 3.573

8.  MicroRNA-10b regulates epithelial-mesenchymal transition by modulating KLF4/Notch1/E-cadherin in cisplatin-resistant nasopharyngeal carcinoma cells.

Authors:  Pei Zhang; Haiyu Hong; Xiaojin Sun; Hao Jiang; Shiyin Ma; Surong Zhao; Mengxiao Zhang; Zhiwei Wang; Chenchen Jiang; Hao Liu
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

9.  MAML1 promotes ESCC aggressiveness through upregulation of EMT marker TWIST1.

Authors:  Mohammad Mahdi Forghanifard; Shirin Azaraz; Sima Ardalan Khales; Dorsa Morshedi Rad; Mohammad Reza Abbaszadegan
Journal:  Mol Biol Rep       Date:  2020-03-16       Impact factor: 2.316

10.  Notch inhibition counteracts Paneth cell death in absence of caspase-8.

Authors:  M K Jeon; E Kaemmerer; U Schneider; M Schiffer; C Klaus; J Hennings; T Clahsen; T Ackerstaff; M Niggemann; A Schippers; T Longerich; G Sellge; C Trautwein; N Wagner; C Liedtke; N Gassler
Journal:  Virchows Arch       Date:  2018-05-16       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.